Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
01:00am, Tuesday, 19'th Aug 2025
August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
12:30pm, Sunday, 17'th Aug 2025
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
10:00am, Saturday, 16'th Aug 2025
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Da
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
12:30pm, Wednesday, 13'th Aug 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advise
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
06:45am, Tuesday, 12'th Aug 2025
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
10:00am, Monday, 11'th Aug 2025
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Da
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
12:38pm, Saturday, 09'th Aug 2025
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advise
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
09:35pm, Thursday, 07'th Aug 2025
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
10:00am, Wednesday, 06'th Aug 2025
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact D
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
argenx SE (ARGX) Q2 2025 Earnings Call Transcript
01:22pm, Thursday, 31'st Jul 2025
argenx SE (NASDAQ:ARGX ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Karen Masse
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
10:00am, Thursday, 31'st Jul 2025
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
01:00am, Thursday, 31'st Jul 2025
$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS foll
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
12:03pm, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised t
